Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study


Por: Tahara, M, Greil, R, Rischin, D, Harrington, KJ, Burtness, B, de Castro, G, Psyrri, A, Braña, I, Neupane, P, Bratland, A, Fuereder, T, Hughes, BGM, Mesía, R, Ngamphaiboon, N, Rordorf, T, Ishak, WZW, Lin, JX, Gumuscu, B, Lerman, N and Soulières, D

Publicada: 15 may 2025 Ahead of Print: 1 abr 2025
Resumen:
Background: Pembrolizumab monotherapy and pembrolizumab-chemotherapy demonstrated superior overall survival (OS) versus cetuximab-chemotherapy (EXTREME) in the primary analysis of the phase III KEYNOTE-048 study of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the first-line setting. We report updated data with 5 years of follow-up. Methods: Adults with previously untreated R/M HNSCC incurable by local therapy were randomly assigned 1:1:1 to pembrolizumab, pembrolizumab plus chemotherapy, or EXTREME. The primary endpoints were OS and progression-free survival (PFS). Results: Overall, 882 participants were assigned to pembrolizumab, pembrolizumab-chemotherapy, or EXTREME. Median study follow-up was 69.2 months (pembrolizumab) and 68.6 months (pembrolizumab-chemotherapy). Median OS remained longer for pembrolizumab versus EXTREME in the programmed cell death ligand 1 (PD-L1) combined positive score (CPS) >= 20 (HR, 0.61; 95 % CI, 0.46-0.81) and CPS >= 1 populations (HR, 0.74; 95 % CI, 0.61-0.89), and similar in the total population (HR, 0.82; 95 % CI, 0.69-0.97). Pembrolizumab-chemotherapy prolonged median OS in the PD-L1 CPS >= 20 (HR, 0.63; 95 % CI, 0.47-0.84), CPS >= 1 (HR, 0.65; 95 % CI, 0.53-0.79), and total (HR, 0.72; 95 % CI, 0.60-0.86) populations. The 5-year OS rate in the total population was 14.4 % for pembrolizumab versus 6.5 % for EXTREME and 16.0 % for pembrolizumab-chemotherapy versus 5.2 % for EXTREME. There was no clinically meaningful difference in PFS among pembrolizumab, pembrolizumab-chemotherapy, or EXTREME groups in any populations. Conclusions: These 5-year follow-up results support the use of pembrolizumab and pembrolizumab-chemotherapy as first-line standards of care for R/M HNSCC. Clinical Trial Information: NCT02358031. Prior Presentation: Presented at the European Society for Medical Oncology Congress, September 9-13, 2022.

Filiaciones:
Tahara, M:
 Natl Canc Ctr Hosp East, 6-5-1 Kashiwanoha, Chiba, Kashiwa 2778577, Japan

Greil, R:
 Paracelsus Med Univ Salzburg, Salzburg Canc Res Inst, Ctr Clin Canc & Immunol Trials, Canc Cluster Salzburg, Salzburg, Austria

Rischin, D:
 Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

 Univ Melbourne, Melbourne, Vic, Australia

Harrington, KJ:
 Inst Canc Res, London, England

Burtness, B:
 Yale Sch Med, New Haven, CT USA

de Castro, G:
 Inst Canc Sao Paulo ICESP, Sao Paulo, Brazil

Psyrri, A:
 Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Athens, Greece

Braña, I:
 Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Barcelona, Spain

Neupane, P:
 Univ Kansas, Med Ctr, Kansas City, KS USA

Bratland, A:
 Oslo Univ Hosp, Oslo, Norway

Hughes, BGM:
 Univ Queensland, Royal Brisbane & Womens Hosp, Herston, Qld, Australia

Ngamphaiboon, N:
 Mahidol Univ, Ramathibodi Hosp, Ratchatewi, Bangkok, Thailand

Rordorf, T:
 Univ Hosp, Zurich, Switzerland

Ishak, WZW:
 Univ Malaya, Fac Med, Dept Clin Oncol, Kuala Lumpur, Malaysia

Lin, JX:
 Merck & Co Inc, Rahway, NJ USA

Gumuscu, B:
 Merck & Co Inc, Rahway, NJ USA

Lerman, N:
 Merck & Co Inc, Rahway, NJ USA

Soulières, D:
 Univ Montreal, Ctr Hosp Univ Montreal, Montreal, PQ, Canada

IGTP, Catalan Inst Oncol, Med Oncol Dept, B ARGO,CARE Program, Badalona, Spain
ISSN: 09598049





European Journal of Cancer
Editorial
Elsevier Ltd., THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 221 Número:
Páginas: 115395-115395
WOS Id: 001477189900001
ID de PubMed: 40262400

MÉTRICAS